Therapies used to control symptoms related to the release of mast-cell mediators in ISM patients grouped according to the sBT slope (<0.15 vs. ≥0.15) after 48 months of follow-up.

Results are expressed as number of cases and percentage between brackets.No statistically significant differences (p >0.05) were found between groups.*Scheduled disodium cromolyn plus scheduled non-sedating or sedating H1 and/or H2 antihistamines, and/or leukotriene antagonists, and/or anxiolytic and/or anti-depression therapy.†Non-sedating or sedating H1 antihistamines and/or corticosteroids and/or epinephrine.